Research graph
References from Prediction of response to Buruli ulcer treatment shortening with novel beta-lactam-containing antimicrobial combinations. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Djakeaux S. Recurrence after surgical treatment of Buruli ulcer in Cote d’Ivoire
2003 · External reference
Relapse after surgical treatment of mycobacterium ulcerans infection (buruli ulcer): study of risk factors in 84 patients in the Democratic Republic of the Congo
2009 · External reference
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease)
2018 · External reference
Long term streptomycin toxicity in the treatment of Buruli ulcer: follow-up of participants in the BURULICO drug trial
10.1371/journal.pntd.0002739 · 2014 · External reference
Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial
10.1016/s0140-6736(20)30047-7 · 2020 · External reference
Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay
10.1371/journal.pntd.0005695 · 2017 · External reference
Oxazolidinones can replace clarithromycin in combination with rifampin in a mouse model of Buruli ulcer
10.1128/aac.02171-18 · 2019 · External reference
Activities of rifampin, rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice
10.1371/journal.pntd.0000933 · 2011 · External reference
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening
10.1371/journal.pntd.0007126 · 2019 · External reference
Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans
10.1371/journal.pntd.0011867 · 2024 · External reference
Unresolved reference
2022 · External reference
Optimizing β-lactam-containing antibiotic combination therapy for the treatment of Buruli ulcer
10.1111/bcp.16209 · 2025 · External reference
Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008
10.2165/11593210-000000000-00000 · 2011 · External reference
How long will treatment guidelines for TB continue to overlook variability in drug exposure?
10.1093/jac/dkz319 · 2019 · External reference
Model-based drug development: a rational approach to efficiently accelerate drug development
10.1038/clpt.2013.54 · 2013 · External reference
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
10.1016/s1473-3099(16)30274-2 · 2017 · External reference
The implications of model-informed drug discovery and development for tuberculosis
10.1016/j.drudis.2016.09.004 · 2017 · External reference
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
10.1056/nejmoa1407426 · 2014 · External reference
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
10.1056/nejmoa1314210 · 2014 · External reference
Buruli Ulcer: a Review of the Current Knowledge
10.1007/s40475-018-0166-2 · 2018 · External reference
Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis
10.1111/bcp.14371 · 2021 · External reference
Clinical and microbiological predictors of healing in Buruli ulcer disease
2024 · External reference
Pharmacokinetics of Rifampin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection
10.1128/aac.00099-10 · 2010 · External reference
Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression
10.1016/j.clpt.2004.10.002 · 2005 · External reference
Therapeutic innovation in drug repurposing: Challenges and opportunities
10.1016/j.drudis.2025.104390 · 2025 · External reference
